ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates
ProMIS Neurosciences' lead therapeutic candidate for Alzheimer’s disease, PMN310, showed an improved safety profile when directly compared to other amyloid-beta directed antibodies, according to preclinical study results. Unlike BAN2401 (Biogen, Eisai) and aducanumab (Biogen), two amyloid-beta directed antibodies both in clinical development, PMN310 did not bind to nontoxic forms of amyloid beta in the Alzheimer's brain, displaying an increased specificity for soluble toxic amyloid beta oligomers. Alzheimer's disease is thought to develop as a consequence of deposits of toxic clumps of the mutant form of amyloid beta protein within the nerve cells of the brain. The brain has three forms of amyloid beta. The toxic form that kills nerve cells and promotes neurodegenerative disease is the oligomer form. Oligomers are a smaller, more toxic version of plaques. Binding of therapeutic antibodies to amyloid beta deposits in brain tissue, particularly in blood vessels, is though to be the underlying cause of the development of ARIA (amyloid-related imaging abnormalities; brain swelling and micro-hemorrhages) in treated Alzheimer's patients. PMN310 is a humanized antibody that attacks only toxic forms of the amyloid beta protein linked to Alzheimer’s, not its normal forms. "PMN310 was designed to selectively target soluble toxic [amyloid beta] oligomers, now widely believed to be a root
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *